Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13281
Abstract: Ibrutinib exerts promising anticancer effects in chronic lymphocytic leukaemia (CLL). However, acquired resistance occurs during treatment, necessitating the exploration of underlying mechanisms. Although three‐dimensional genome organization has been identified as a major player in the… read more here.
Keywords: pak1; ibrutinib resistant; chronic lymphocytic; chromosome conformation ... See more keywords
A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant BtkC481S mutation in B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14809
Abstract: Bruton's tyrosine kinase (BTK) plays a key role in B‐cell receptor signalling by regulating cell proliferation and survival in various B‐cell malignancies. Covalent low‐MW BTK kinase inhibitors have shown impressive clinical efficacy in B‐cell malignancies.… read more here.
Keywords: resistant btkc481s; btkc481s mutation; cell malignancies; ibrutinib resistant ... See more keywords
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer research"
DOI: 10.1158/0008-5472.can-17-2485
Abstract: The clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged by the frequent emergence of resistant clones. The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B-cell receptor signaling, and… read more here.
Keywords: cll; ibrutinib; lymphocytic leukemia; cll cells ... See more keywords
Ibrutinib-resistant CLL: unwanted and unwonted!
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood-2017-01-761536
Abstract: In this issue of Blood, Ahn et al find intriguing clinical and molecular differences between early and late relapsing patients in a phase 2 trial of chronic lymphocytic leukemia (CLL) treated with ibrutinib.1 read more here.
Keywords: resistant cll; cll; ibrutinib resistant; unwanted unwonted ... See more keywords
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Haematologica"
DOI: 10.3324/haematol.2022.281538
Abstract: Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma characterized by frequent relapses. The development of resistance to ibrutinib therapy remains a major challenge in MCL. We previously showed that glutaminolysis is associated with… read more here.
Keywords: cell; ibrutinib; ibrutinib resistant; cell lymphoma ... See more keywords